Arrowhead Research | ARWR - Debt



Arrowhead Research reported $388.24M in Debt for its fiscal quarter ending in March of 2025.


Debt Change Date
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Arrowhead Research USD 388.24M 21.18M Mar/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
Ligand Pharmaceuticals USD 24K 0 Mar/2025
Merck USD 34.84B 2.27B Mar/2025
Moderna USD 741M 4M Jun/2025
Novartis USD 31.27B 12M Mar/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
TG Therapeutics USD 8.98M 235.45M Mar/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025
Xencor USD 67.93M 86.45M Jun/2025